Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH

NCT02392559 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02392559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02392559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 24, 2016
Completion date
November 25, 2019
Enrollment
158 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia